Sequential high-dose melphalan and busulfan/cyclophosphamide followed by peripheral blood progenitor cell rescue, interferon/thalidomide and pamidronate [pamidronic acid] for patients with multiple myeloma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Busulfan; Cyclophosphamide; Interferon alpha; Melphalan; Pamidronic acid; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Jul 2019 Biomarkers information updated
- 17 Dec 2013 Planned end date changed from 1 Jul 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 26 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.